论文部分内容阅读
目的:检测卵巢上皮性癌(EOC)患者外周血可溶性肿瘤坏死因子样凋亡微弱诱导剂(sTWEAK)的表达水平,并分析其临床意义。方法:选取2010年1月至2014年2月在上海交通大学附属仁济医院住院行手术的上皮性卵巢癌(EOC)患者和良性上皮性卵巢肿瘤患者共43例,采用ELISA法检测外周血血清中sTWEAK的表达水平。结果:(1)与良性上皮性卵巢肿瘤组相比,EOC组的sTWEAK的表达水平明显升高(P<0.05)。两组患者中sTWEAK的表达与CA125呈正相关(r=0.42,P<0.05),其中CA125<500U/ml者的sTWEAK表达水平明显低于CA125>500U/ml者(P<0.05)。(2)EOC患者血清中,sTWEAK的表达水平与其临床分期、病理分级、组织类型以及腹水有无肿瘤细胞均无相关性(P>0.05)。(3)EOC组中,CA125<500U/ml者行满意肿瘤细胞减灭术的比例显著高于CA125>500U/ml者(P<0.05)。结论:sTWEAK虽不能反映EOC患者的肿瘤进展,但其与EOC的发生密切相关,sTWEAK可能成为判断卵巢肿瘤良恶性的新型血清学标记,在EOC诊断及预后预测中具有一定的应用前景。
Objective: To detect the expression level of sTWEAK in peripheral blood of patients with epithelial ovarian cancer (EOC) and to analyze its clinical significance. Methods: Forty-three patients with epithelial ovarian cancer (EOC) and benign epithelial ovarian cancer who underwent surgery in Renji Hospital Affiliated to Shanghai Jiaotong University from January 2010 to February 2014 were enrolled in this study. Peripheral blood serum In sTWEAK expression levels. Results: (1) The expression of sTWEAK in EOC group was significantly higher than that in benign epithelial ovarian tumor (P <0.05). The expression of sTWEAK in both groups was positively correlated with CA125 (r = 0.42, P <0.05). The expression of sTWEAK in CA125 <500U / ml was significantly lower than that in CA125> 500U / ml (P <0.05). (2) The expression level of sTWEAK in EOC patients serum had no correlation with clinical stage, pathological grade, histological type and ascites presence or absence of tumor cells (P> 0.05). (3) In the EOC group, the proportion of satisfactory tumor cytoreductive surgery patients with CA125 <500 U / ml was significantly higher than those with CA125> 500 U / ml (P <0.05). Conclusion: Although sTWEAK can not reflect the tumor progression of patients with EOC, it is closely related to the occurrence of EOC. STWEAK may be a new serological marker for the diagnosis of benign and malignant ovarian tumors. It may have some potential applications in diagnosis and prognosis of EOC.